Enhancing Compressive Strength in M45 Grade Concrete: A Comparative Evaluation of Micro-silica and Alccofine as Partial Cement Replacements
Pokhara Engineering College Journal · 2025
DOI: 10.3126/pecj.v2i2.81739 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pokhara Engineering College Journal, 2025. Verfasst von Santosh G.C. und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This study investigates the compressive strength and durability of M45 grade concrete using Micro-silica and Alccofine as partial replacements for cement. Experimental results indicate that Alccofine-based concrete achieves 28-day compressive strengths of up to 60.6 MPa at 10% replacement, outperforming Micro-silica-based mixes by 55.2 MPa. Alccofine also enhances workability, with slump values peaking at 144 mm and 135 mm for Micro-silica. The optimal replacement level for both materials is 10% by cement volume, where Alccofine’s dual pozzolanic-cementitious reactivity improves microstructure densification, reducing permeability and enhancing durability. These findings position Alccofine as a superior additive for high-strength concrete applications, offering significant mechanical and durability advantages.
Zitieren
APA
G.C., S., & Koirala, S. (2025). Enhancing Compressive Strength in M45 Grade Concrete: A Comparative Evaluation of Micro-silica and Alccofine as Partial Cement Replacements. Pokhara Engineering College Journal. https://doi.org/10.3126/pecj.v2i2.81739
Vancouver
G.C. S, Koirala S. Enhancing Compressive Strength in M45 Grade Concrete: A Comparative Evaluation of Micro-silica and Alccofine as Partial Cement Replacements. Pokhara Engineering College Journal. 2025. doi:10.3126/pecj.v2i2.81739
BibTeX
@article{GC2025,
author = {G.C., Santosh and Koirala, Sudeep},
title = {Enhancing Compressive Strength in M45 Grade Concrete: A Comparative Evaluation of Micro-silica and Alccofine as Partial Cement Replacements},
journal = {Pokhara Engineering College Journal},
year = {2025},
doi = {10.3126/pecj.v2i2.81739}
}
EUVIMED